Desenvolvimento e caracterização de nanopartículas lipídicas contendo topotecano
Guardado en:
| Autor principal: | |
|---|---|
| Fecha de Publicación: | 2010 |
| Formato: | Master thesis |
| Lenguaje: | por |
| Fuente: | Repositório Institucional da UFG |
| Download full: | http://repositorio.bc.ufg.br/tede/handle/tde/2091 |
Sumario: | Topotecan (TPT), hydrophilic semisynthetic analogue of camptothecin, is a topoisomerase I inhibitor anticancer agent. Encapsulation of TPT in nanocarriers can protect him from inactivation on plasmatic pH and P-glycoprotein (P-gp) mediated resistance. In this study, solid lipid nanoparticles (SLN) were produced by three different methods: cold high pressure homogenization (CHPH), double emulsion prepare (DEMP) and microemulsion dilution (MMD). Derivative systems from NLS, nanostructured lipid carriers (NLC) were produced only by MMD. Temperature proved to be a limiting factor in producing nanoparticles loaded TPT and must be strictly controlled. Nanoparticles produced by MMD (SLN and NLC) presented best encapsulation efficiency, drug loading and particle size distribution. These particles presented 150 nm average diameter, 0.2 PdI and -45 mV average zeta potential. Despite the hydrophilic drugs encapsulation to be a hard work, lipid nanoparticles loaded TPT presented 6% drug loading and an encapsulation efficiency biggest then 95%. Encapsulation of TPT in lipid nanoparticles sustained drug release by 12 hours and protected the drug from degradation at pH 7,4 at 37°C. Drug nanoencapsulation also increased his citotoxicity on K562 leucemic cells at 2 and 24 hours. There weren t differences between NLC and SLN on release, citotoxicity and stability studies. Threalose was an efficient cryoprotector on lyophilization of SLN and NLC loaded TPT. Lyophilizates NLC and SLN with 15% of threalose stayed stable almost for 30 days. Nanostructured lipid carriers with high topotecan chloridrate loading obtained in this work presented potential to improve clinical efficacy associated with parenteral administration of this important citotoxic drug. |
Ejemplares similares: Desenvolvimento e caracterização de nanopartículas lipídicas contendo topotecano
- Desenvolvimento de sistemas lipídicos nanoestruturados contendo paclitaxel: estudos de permeação cutânea
- Desenvolvimento de formulações semissólidas contendo topotecano encapsulado em carreadores lipídicos nanoestruturados para aplicação tópica
- Desenvolvimento de nanopartículas lipídicas e associação de iontoforese para administração transdérmica do lopinavir
- Desenvolvimento de carreadores lipídicos nanoestruturados contendo extrato de Centella asiatica (L.) Urban para uso tópico
- Desenvolvimento de formulações contendo voriconazol encapsulado em nanopartículas lipídicas e promotores químicos de absorção para aplicação tópica na unha
- Desenvolvimento e caracterização de carreador lipídico nanoestruturado contendo curcumina
